Victoria Johnson

A VR exergame may facilitate patients’ physical activity while promoting relaxation and positive mental states.

Recommendations have been largely preserved since 2018 and the USPSTF acknowledged the need for more research and better risk assessment tools.

However, gout flare states of patient acceptable symptom state, low disease activity, or not achieving either were not associated with EQ-5D-3L or HAQ.

Investigators found an incidence of 26.2 severe infections per 100 patient-years with 4 deaths in the study.

Small molecule drugs may help fill gaps in treatment with biologic therapies.

Tocilizumab and other biological drugs were particularly efficacious in lowering overall hemostatic potential, mitigating blood clot risks.

Around 37% of those had never used a bDMARD reached sustained DMARD-free remission at 5 years,

Despite improvements in PROs and disease activity, no statistically significant changes have been seen on blood biomarker analysis.

The rheumatology month in review emphasizes new research in PsA and on cardiovascular events in rheumatic disease.

An active comparator study found that incident use of gabapentin was associated with lower rates of falls than duloxetine and similar rates of severe falls.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

Other recent research presented at ACR 2024 found increased CVD risk with glucocorticosteroid use.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

This year in review spotlights top rheumatology FDA news from 2024 and new research out of the ACR 2024 Convergence.

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.

These findings, from an observational study, should be confirmed in a randomized, controlled trial.

The rheumatology month in review emphasizes new data from ACR 2024 in lupus, gout, and fibromyalgia.

Women who gave birth after infertility without receiving fertility treatments had an elevated risk of developing SARDs, such as lupus.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

CDC, NIH, and AMA recommend PEMs to be at a 6th-to-8th-grade reading level, while assessed materials were readable at high school or higher levels.

CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence.

The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

At the highest dose levels, mean plasma urate levels remained below 6.0 mg/dL for up to 12 weeks.

Stone discussed the phase 3 MITIGATE study, other potential treatment strategies, and top research priorities moving forward for IgG4.

Patients in the anifrolumab arm also had lower rates of damage accrual.